Crosstalk between PPARs and gut microbiota in NAFLD

Biomed Pharmacother. 2021 Apr:136:111255. doi: 10.1016/j.biopha.2021.111255. Epub 2021 Jan 20.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disorder in both China and worldwide. It ranges from simple steatosis and progresses over time to nonalcoholic steatohepatitis (NASH), advanced liver fibrosis, cirrhosis, or hepatocellular carcinoma(HCC). Furthermore, NAFLD and its complications impose a huge health burden to society. The microbiota is widely connected and plays an active role in human physiology and pathology, and it is a hidden 'organ' in determining the state of the host, in terms of homeostasis, or disease. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptorsuperfamily and can regulate multiple pathways involved in metabolism, and serve as effective targets forthe treatment of many types of metabolic syndromes, including NAFLD. The purpose of this review is to integrate related articles on gut microbiota, PPARs and NAFLD, and present a balanced overview on how the microbiota can possibly influence the development of NAFLD through PPARs.

Keywords: Gut microbiota; NAFLD; PPAR.

Publication types

  • Review

MeSH terms

  • Animals
  • Bacteria / metabolism*
  • Gastrointestinal Microbiome*
  • Humans
  • Intestines / microbiology*
  • Liver / metabolism*
  • Non-alcoholic Fatty Liver Disease / metabolism*
  • Non-alcoholic Fatty Liver Disease / microbiology*
  • Peroxisome Proliferator-Activated Receptors / metabolism*
  • Signal Transduction

Substances

  • Peroxisome Proliferator-Activated Receptors